T. Rowe Price Associates’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-44,200
| Closed | -$24K | – | 3098 |
|
|
2024
Q4 | $24K | Hold |
44,200
| – | – | ﹤0.01% | 2979 |
|
|
2024
Q3 | $78K | Hold |
44,200
| – | – | ﹤0.01% | 2865 |
|
|
2024
Q2 | $52K | Buy |
44,200
+13,271
| +43% | +$15.6K | ﹤0.01% | 2850 |
|
|
2024
Q1 | $280K | Buy |
30,929
+2,624
| +9% | +$23.8K | ﹤0.01% | 2465 |
|
|
2023
Q4 | $308K | Buy |
28,305
+936
| +3% | +$10.2K | ﹤0.01% | 2362 |
|
|
2023
Q3 | $221K | Buy |
27,369
+1,571
| +6% | +$12.7K | ﹤0.01% | 2463 |
|
|
2023
Q2 | $281K | Buy |
25,798
+6,098
| +31% | +$66.4K | ﹤0.01% | 2390 |
|
|
2023
Q1 | $136K | Sell |
19,700
-3,400
| -15% | -$23.5K | ﹤0.01% | 2622 |
|
|
2022
Q4 | $92K | Buy |
23,100
+7,500
| +48% | +$29.9K | ﹤0.01% | 2735 |
|
|
2022
Q3 | $104K | Hold |
15,600
| – | – | ﹤0.01% | 2715 |
|
|
2022
Q2 | $76K | Buy |
15,600
+4,417
| +39% | +$21.5K | ﹤0.01% | 2804 |
|
|
2022
Q1 | $105K | Buy |
+11,183
| New | +$105K | ﹤0.01% | 2829 |
|
|
2021
Q2 | – | Sell |
-42,186
| Closed | -$653K | – | 2952 |
|
|
2021
Q1 | $653K | Buy |
+42,186
| New | +$653K | ﹤0.01% | 2233 |
|
|
2018
Q4 | – | Sell |
-102,165
| Closed | -$4.09M | – | 2588 |
|
|
2018
Q3 | $4.09M | Buy |
+102,165
| New | +$4.09M | ﹤0.01% | 1478 |
|
|
2018
Q1 | – | Sell |
-104,075
| Closed | -$3.4M | – | 2567 |
|
|
2017
Q4 | $3.4M | Buy |
+104,075
| New | +$3.4M | ﹤0.01% | 1460 |
|